ACS angiography planning should not stop at choosing the wrist. Radial access is preferred when feasible, but femoral backup, crossover triggers, radial spasm and possible mechanical circulatory support need to be anticipated before the case becomes unstable.

Acute pulmonary embolism can look deceptively stable before blood pressure falls. This teaching keeps risk stratification dynamic, using right ventricular dysfunction, oxygenation, lactate, troponin and trajectory to separate low, intermediate-high and high-risk PE.

Stable chest discomfort may need anatomy, physiology and plaque burden considered together. CCTA can show coronary atherosclerosis directly; CT-FFR and CAD-RADS modifiers help interpret lesion-specific flow limitation, plaque burden and high-risk plaque features.

Heart failure with broad left bundle branch block needs CRT decisions grounded in response, anatomy and evidence limits. Biventricular pacing remains the guideline-supported first-line strategy for typical reduced ejection fraction, while left bundle branch area pacing raises capture, expertise and selection questions.

Complex atrial fibrillation is framed around the decision that changes management: rhythm control, rate control, cardioversion, ablation or pacing. Pre-excitation, pregnancy, repaired Tetralogy of Fallot and tachy-brady syndrome each need a more precise description than chronic AF.

Cardiology history is mainly for physiology-minded learners. It still helps when chest pain, valve disease or hypertrophic cardiomyopathy feels mechanical: heart rate, wall tension, contractility and dynamic gradients explain why bedside anomalies deserve careful checking.

Chest pain, hypoxia, presyncope or collapse with acute PE risk makes this the first thing to open. It clarifies structured risk stratification, when systemic thrombolysis belongs in high-risk PE, and how bleeding risk and anticoagulation decisions should be documented early.

Cancer-treatment dyspnoea and falling exercise tolerance are the clinical entry points here, not the drug name alone. The useful move is surveillance: baseline risk, serial echocardiography, global longitudinal strain, and biomarkers matter, while the SGLT2 story remains promising but still early.

The key lesson is to stop treating palliative care as the final chapter of heart failure. Recurrent admissions, worsening renal function, escalating diuretics or shock should trigger earlier serious illness conversations, better choice awareness around LVAD or supportive care, and clearer hospice handover.

LVAD troubleshooting starts with physiology, not pump numbers alone. A new low-flow alarm with rising vasopressor need or high central venous pressure should trigger rapid assessment for right ventricular failure or tamponade, while blood pressure, rhythm, filling and echo often explain controller changes.